Q4 2024 Protalix Biotherapeutics Inc Earnings Call Transcript
Key Points
- Protalix BioTherapeutics Inc (PLX) achieved record revenues in 2024, driven by increased sales to partners like Chiesi and Pfizer.
- The company fully repaid its outstanding debt, strengthening its balance sheet.
- Protalix is advancing its R&D efforts, particularly with PRX-115, which completed a successful Phase 1 trial and is preparing for Phase 2.
- The European Medicines Agency validated a new dosing regimen for Elfabrio, potentially expanding its market in the EU.
- Protalix's collaboration with Chiesi is progressing well, with expectations of significant revenue growth from royalties by 2030.
- Revenues from license and R&D services decreased by 98% due to the completion of the Elfabrio program.
- The company expects minimal future revenues from license and R&D services, aside from potential milestone payments.
- Net income decreased from $8.3 million in 2023 to $2.9 million in 2024, indicating a decline in profitability.
- Research and development expenses decreased by 24%, which may impact the pace of new product development.
- Protalix did not provide specific revenue guidance for 2025, creating uncertainty about future financial performance.
Good morning, ladies and gentlemen, and welcome to the Protalix Biotherapeutics fiscal year 2024 financial and business results conference call.
As a reminder, this conference call is being recorded. I'll now turn the conference over to your host, Mr. Mike Moyer of LifeSci Advisors, Investor Relations, for Protalix. You may begin your conference.
Thank you, operator, and welcome to the Protalix Biotherapeutics fiscal year 2024 financial results and business update conference call. With me today are Dror Bashan, President and CEO of Protalix; and Eyal Rubin, Senior Vice President & Chief Financial Officer.
A press release announcing the financial results and corporate updates was issued this morning and is available now on the Protalix website. Please take a moment to read the disclaimer about forward-looking statements in the press release. The earnings release in this teleconference include forward-looking statements. These forward-looking statements are subject to known and unknown
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
